Consensus Tilray Brands, Inc.

Equities

TLRY

US88688T1007

Market Closed - Nasdaq Other stock markets 21:00:00 13/09/2024 BST			After market 00:00:10
1.740 ^USD	+2.35%		1.735	-0.29%

09-12	Tilray Brands Closes Atwater Brewery Acquisition From Molson Coors Beverage	MT
09-09	Tilray Medical Supports Scientific Study on Fibromyalgia With "Positive Outcomes"	MT

Evolution of the Average Target: Tilray Brands, Inc.

Evolution of the Target Price: Tilray Brands, Inc.

Changes in Analyst Recommendations: Tilray Brands, Inc.

2.wA1T1NOs64u7GTtzgfYoTmHRYNLrcSjEmElfk6s6nLc.iUAM5efzidLRSlpHxoVgGROOJbDZKRmr7Xo5ptFT8_COXGSL5eWO28tzcg~b983aecc359a3bb552d44e74e8c03064

Analysts' recommendations: Tilray Brands, Inc.

Social Buzz: Wallstreetbets Stocks Advance Premarket Friday; Reddit, AMC Entertainment to Open Higher	05-17	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Monday; MicroStrategy, Tesla to Advance	04-08	MT
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	03-22	MT
Tilray Brands Declines More Than 5%, ATB Capital Lowers Price Target	01-10	MT
TD Cowen Trims Tilray Brands Price Target to $2.50 From $3, Maintains Outperform Rating	06/10/23	MT
TD Cowen Cuts Tilray Brands' Price Target to $5 From $9, Keeps Outperform Rating	11/04/23	MT
Alliance Global Partners Adjusts Price Target on Tilray Brands to $3 From $4, Maintains Neutral Rating	10/01/23	MT
Bernstein Starts Tilray Brands at Market Perform With $3.90 Price Target	02/11/22	MT
Cantor Fitzgerald Adjusts Tilray Brands' Price Target to $4.50 from $4.15, Maintains Neutral Rating	10/10/22	MT
Barclays Adjusts Price Target on Tilray Brands to $2 From $4.50, Maintains Underweight Rating	30/09/22	MT
MKM Partners Adjusts Tilray Brands Price Target to $5 From $8, Maintains Neutral Rating	12/08/22	MT
Cantor Fitzgerald Adjusts Tilray Brands' Price Target to $4.15 From $5.75, Keeps Neutral Rating	02/08/22	MT
Stifel Lowers Tilray Brands' Price Target to $3.30 From $5.50, Hold Rating Maintained	01/08/22	MT
Benchmark Capital Downgrades Tilray Brands to Sell From Hold; Price Target is $3	29/07/22	MT
Jefferies Lowers Tilray Brands Price Target to $12.10 From $15.60, Maintains Buy Rating	26/07/22	MT
Roth Capital Adjusts Tilray Brands' Price Target to $4 From $8, Maintains Neutral Rating	15/07/22	MT
Canaccord Genuity Lowers Tilray Brands' Price Target to $7 From $9, Buy Rating Maintained	15/06/22	MT
Piper Sandler Adjusts Tilray Brands' Price Target to $3 From $6, Maintains Neutral Rating	15/06/22	MT
Barclays Adjusts Tilray's Price Target to $4.50 From $8.50, Keeps Underweight Rating	20/04/22	MT
Piper Sandler Reviews Tilray's Q3 Results, Says US$4 Billion Annual Revenue Run-Rate Target "Difficult to Achieve"	07/04/22	MT
Cantor Fitzgerald Adjusts Tilray's Price Target to $8.40 from $6.90, Keeps Neutral Rating	07/04/22	MT
Piper Sandler Lowers Tilray Target to US$6, Keeps Neutral Rating	17/03/22	MT
Piper Sandler Adjusts Tilray's Price Target to $6 From $8, Maintains Neutral Rating	17/03/22	MT
Canaccord Genuity Upgrades Tilray to Buy from Hold, Keeps $9 Price Target	04/03/22	MT
Canaccord Lowers Tilray's Price Target to $9 From $12, Maintains Hold Rating	11/01/22	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	TILRAY BRANDS, INC.					+33.83%
	ELI LILLY AND COMPANY					+7.76%
	NOVO NORDISK A/S					+5.34%
	JOHNSON & JOHNSON					+3.51%
	ABBVIE INC.					+1.08%
	MERCK & CO., INC.					+19.99%
	ROCHE HOLDING AG					+11.85%
	ASTRAZENECA PLC					+17.35%
	NOVARTIS AG					+0.65%
	AMGEN INC.					-2.33%
	Average					+9.90%
	Weighted average by Cap.					+7.19%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.740USD

Average target price

2.329USD

Spread / Average Target

+33.83%

High Price Target

4.000USD

Spread / Highest target

+129.89%

Low Price Target

1.900USD

Spread / Lowest Target

+9.20%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

ATB Capital
TD Cowen
Alliance Global Partners
Bernstein
Cantor Fitzgerald
Barclays
MKM Partners
Stifel Nicolaus
Benchmark Capital
Jefferies & Co.
Roth Capital Partners
Canaccord Genuity
Piper Sandler
CIBC World Markets
Consumer Edge
Cowen
BofA Securities